Squarepoint’s Marker Therapeutics MRKR Stock Holding History

Squarepoint’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$36.9K	Buy	+34,485	New	+$43.7K	﹤0.01%	4308
2025 Q2	–	Sell	-43,302	Closed	-$53.3K	–	4846
2025 Q1	$53.3K	Buy	+43,302	New	+$79.3K	﹤0.01%	4334
2021 Q2	–	Sell	-1,086	Closed	-$24K	–	3527
2021 Q1	$24K	Sell	1,086 -1,940	-64%	-$44.4K	﹤0.01%	3023
2020 Q4	$44K	Buy	+3,026	New	+$47K	﹤0.01%	2810
2020 Q2	–	Sell	-1,324	Closed	-$25K	–	2413
2020 Q1	$25K	Buy	1,324 +60	+5%	+$1.53K	﹤0.01%	1769
2019 Q4	$36K	Buy	+1,264	New	+$46K	﹤0.01%	2411
2019 Q2	–	Sell	-2,256	Closed	-$149K	–	2566
2019 Q1	$149K	Buy	+2,256	New	+$132K	﹤0.01%	1993

Other funds holding MRKR

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Ashton Thomas Private Wealth Scottsdale, Arizona $4.98B AUM 21.09% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Squarepoint's MRKR Position: Q3 2026 in Review

Squarepoint opened a new position in Marker Therapeutics (MRKR) in Q3 2026: 34,485 shares worth $36.9K. The stake represents ﹤0.01% of the portfolio and ranks #4308 among its holdings. This is a return to the name: Squarepoint previously reported a position in MRKR as recently as Q1 2025.

Squarepoint first reported a position in MRKR in Q1 2019 and has held it in 7 quarters since. The position peaked at $149K in Q1 2019. 22 funds tracked by Wall St. Rank hold MRKR as of Q3 2026.

Squarepoint held 34,485 shares of Marker Therapeutics worth $36.9K as of Q3 2026.
Marker Therapeutics was a new Squarepoint position in Q3 2026.
Marker Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4308 holding.
Squarepoint first reported a position in Marker Therapeutics in Q1 2019 and has held it in 7 quarters since.
Squarepoint's Marker Therapeutics position peaked at $149K in Q1 2019.
22 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.